• Welcome to Adipoa-2

    Osteoarthritis is an incurable and debilitating disease that affects over 70 million Europeans.

  • The problem

    There are currently no effective therapies to prevent progression of the disease.

  • The project

    ADIOPOA-2 is a developing a novel cellular therapy to treat osteoarthritis.

The Project

ADIPOA-2 is developing a novel cellular therapy to treat osteoarthritis.

Osteoarthritis (OA) is an incurable and debilitating disease. It has been identified as the world’s eleventh highest contributor to disability and affects over 70 million Europeans. There is currently no treatment to prevent progression of the disease.

ADIPOA-2 will build on the work of ADIPOA to deliver a large-scale clinical trial in regenerative medicine for OA. The purpose of the project is to design and implement a phase IIb study to assess the safety and efficacy of autologous (patient-derived) ACSs in the treatment of advanced OA of the knee. The cells will be prepared from samples of adipose tissue harvested from patients by lipoaspiration.

ADIPOA2 discussed at A FACTT meeting

 ADIPOA2 was one of a number of projects discussed at the A FACTT meeting in Galway this week. A FACTT is an Action to Focus and Accelerate Cell-based Tolerance-Inducing Therapies, funded through the COST (European Cooperation in Science and Technology) Programme. The meeting is being hosted by NUIG and runs from 5-7 October.

The Team

The Adipoa-2 team comes from a variety of backgrounds and academic disciplines.
They share an interest in good science for the service of public health, and have been
selected and recruited specifically to cover all angles a project like Adipoa-2 requires.